MwanzoGIFOF • OTCMKTS
add
Grifols SA Preference Shares Class B
Bei iliyotangulia
$ 7.42
Bei za mwaka
$ 5.58 - $ 9.40
Thamani ya kampuni katika soko
5.97B USD
Wastani wa hisa zilizouzwa
10.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.79B | 12.24% |
Matumizi ya uendeshaji wa biashara | 376.78M | -3.08% |
Mapato halisi | 51.69M | -13.19% |
Kiwango cha faida halisi | 2.88 | -22.79% |
Mapato kwa kila hisa | — | — |
EBITDA | 468.09M | 33.73% |
Asilimia ya kodi ya mapato | 31.35% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 806.74M | 66.60% |
Jumla ya mali | 20.28B | -8.07% |
Jumla ya dhima | 12.29B | -8.95% |
Jumla ya hisa | 8.00B | — |
hisa zilizosalia | 679.63M | — |
Uwiano wa bei na thamani | 0.94 | — |
Faida inayotokana na mali | 4.22% | — |
Faida inayotokana mtaji | 4.78% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 51.69M | -13.19% |
Pesa kutokana na shughuli | 299.61M | 92.51% |
Pesa kutokana na uwekezaji | -196.40M | -59.83% |
Pesa kutokana na ufadhili | -1.56B | -1,860.81% |
Mabadiliko halisi ya pesa taslimu | -1.47B | -3,652.69% |
Mtiririko huru wa pesa | 243.60M | 627.76% |
Kuhusu
Grifols, S.A. is a global healthcare company and manufacturer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,000employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceutical solutions, the company is also a leader in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Its portfolio of solutions is designed to enhance safety from donation to transfusion. Grifols also provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. Additionally, the company supply tools, information and services that enable hospitals, pharmacies and healthcare professionals to deliver expert medical care. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
18 Nov 1940
Tovuti
Wafanyakazi
23,000
